Embody closed a $9.3 million Series A funding round. Proceeds will support new hires and the commercial 2H20 launch of the Tapestry® collagen-based microfiber implant for Achilles tendon and rotator cuff repairs.
Tapestry’s design is based on research of collagen increasing the activity of recellularization by growing new aligned tissue over surgical repairs. The collagen-based nanofiber graft, formed with electrospinning and microfluidic fabrication techniques, is resorbable and designed to mimic the architecture of the native tendon.
“This financing represents a significant step in the growth of Embody,” said Jeff Conroy, Embody’s Co-founder and Chief Executive Officer. “We are now in a position to execute on our goals of commercializing Tapestry, our first in a series of soft tissue repair products for Achilles, rotator cuff and knee ligament injuries.”
Embody closed a $9.3 million Series A funding round. Proceeds will support new hires and the commercial 2H20 launch of the Tapestry® collagen-based microfiber implant for Achilles tendon and rotator cuff repairs.
Tapestry's design is based on research of collagen increasing the activity of recellularization by growing new aligned tissue over...
Embody closed a $9.3 million Series A funding round. Proceeds will support new hires and the commercial 2H20 launch of the Tapestry® collagen-based microfiber implant for Achilles tendon and rotator cuff repairs.
Tapestry’s design is based on research of collagen increasing the activity of recellularization by growing new aligned tissue over surgical repairs. The collagen-based nanofiber graft, formed with electrospinning and microfluidic fabrication techniques, is resorbable and designed to mimic the architecture of the native tendon.
“This financing represents a significant step in the growth of Embody,” said Jeff Conroy, Embody’s Co-founder and Chief Executive Officer. “We are now in a position to execute on our goals of commercializing Tapestry, our first in a series of soft tissue repair products for Achilles, rotator cuff and knee ligament injuries.”
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
